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Identity 
Other names: ADAM18; CD156B; CSVP; 
MGC71942; TACE 
HGNC (Hugo): ADAM17 
Location: 2p25.1 
Note: There are several recommendable reviews about 
ADAM17 and related proteases, for example Blobel, 
2005; Arribas and Esselens, 2009; Gooz, 2010; and 
Saftig and Reiss, 2011. 
DNA/RNA 
Description 
The genomic DNA of ADAM17 extends 66505 base 
pairs with 19 exons. There is only one known 
transcription variant. 
Transcription 
The mRNA of ADAM17 (NM_003183.4) contains 
3572 base pairs and the open reading frame spans from 
bp 184 to bp 2658. Different isoforms due to 
differential splicing are not known. 
Pseudogene 
No pseudogenes have been reported for ADAM17. 
Protein 
Note 
ADAM17 belongs to the ADAM (a disintegrin and 
metalloprotease) family which is part of the adamalysin 
proteins. 
The activity and function of several membrane proteins 
is regulated by the proteolytic release of their 
ectodomains, a process known as shedding. About 2-
4% of the proteins on the cell surface are affected by 
ectodomain shedding (Arribas and Massague, 1995). 
Since there are several of functionally and structurally 
diverse substrates, ADAMs are involved in various 
cellular processes. They take part in the regulation of 
cell adhesion, migration, development and signalling 
and are also implicated in pathologic conditions such as 
inflammation and cancer. The consequences of 
ectodomain shedding can vary, depending on the 
function of the substrate protein. Membrane-bound 
precursor proteins can be released by ADAMs as 
mature active molecules, for example ligands of the 
EGF receptor or cytokines like TNFa (Peschon et al., 
1998; Blobel, 2005). Receptors, for example ErbB2 and 
ErbB4, can also be cleaved by ADAMs and thus 
become inactive or may still function as soluble decoy 
receptors (Molina et al., 2001; Vecchi et al., 1998). 
Contrariwise, receptors like Notch require proteolytic 
cleavage to generate intracellular signalling fragments 
that act as transcription factors after translocatin o the 
nucleus. In this case ectodomain shedding is the 
prerequisite for regulated intramembrane proteolysis 
(RIP) mediated by intramembrane cleaving enzymes 
(Pan and Rubin, 1997; Brou et al., 2000). 
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The structure of "a disintegrin and metalloproteases" consists of a N-terminal prodomain (aa 1-214) followed by a metalloprotease 
domain (aa 223-477), a disintegrin domain (aa 484-560) with a cystein-rich region, an epidermal growth factor-like domain (EGF) (aa 
571-602), a transmembrane domain (TM) (aa 672-694) and a cytoplasmic tail (aa 695-824) (Arribas and Esselens, 2009 - modified). 
Amino acid specifications according to Pubmed graphics for ADAM17 (NP_003174.3). 
 
Description 
The preproform of ADAM17 contains 824 amino acids 
(134 kDa). After cleavage of the prodomain by furin or 
other proprotein convertases, the mature form has a 
predicted molecular weight of 98 kDa. The prodomain 
serves as a chaperone and keeps the enzyme in an 
inactive state during maturation in the trans-Golgi 
network (Schlöndorff et al., 2000). The catalytic 
domain contains the characteristic zinc binding motif 
(HEXXHXXGXXH) and three potential N-
glycosylation sites. The disintegrin domain is discussed 
to be involved in regulation of the catalytic activity of 
ADAM17 (Li and Fan, 2004; Smith et al., 2002), but 
might also be involved in interaction with integrins and 
therefore mediate cell-cell adhesion or cell-matrix 
interaction. The cytoplasmic tail of ADAM17 was 
thought to be important in regulation of the enzyme 
activity because of its potential tyrosine 
phosphorylation site, but recent studies showed that
overexpressed ADAM17 lacking its cytoplasmic 
domain was able to cleave TNFalpha upon phorbolester 
stimulation (Reddy et al., 2000; Horiuchi et al., 2007). 
The transmembrane domain might play a role in 
regulation of ADAM activity as studies with ADAM-
chimera with exchanged transmembrane domains and 
experiments with plasma membrane modulating stimuli 
indicate (Le Gall et al., 2010; Reiss et al., 2011). 
Expression 
ADAM17 is ubiquitously expressed in various tissues, 
for example in the brain, kidney, heart and skeletal 
muscles. The expression pattern changes during 









ADAM17 is a type I transmembrane protein, but only 
10% of the total protein can be found in the plasma 
membrane on the cell surface (Schlöndorff et al., 
2000). Most of the protein is localised in the 
endoplasmic reticulum and trans-Golgi network. It is 
suggested that ADAM17 accumulates in cholesterol 
rich departments of the plasma membrane (lipid rafts) 
(Tellier et al., 2006). 
Function 
ADAM17 knockout mice display a severe  
phenotype that resembles mice lacking the epidermal 
growth factor receptor (EGFR) or one of its ligands 
(TGFalpha, HB-EGF or amphiregulin). Perinatal 
mortality is probably due to defects in heart 
development. 
Because of their catalytic and their disintegrin domain, 
ADAMs can have both adhesive and proteolytic 
functions. ADAM17 is best studied for its proteolytic 
properties and cleaves its substrates in the 
juxtamembrane region. The proteins processed by 
ADAM17 have different functions and therefore 
proteolytic processing can either activate or abrogate 
processes. For example both receptors and ligands can 
be cleaved, thus signalling can be either initiated or 
stopped by ADAM17. 
Homology 
Homologs of the human ADAM17 are found in various 
species ranging from other mammalians to primitive 
chordates like zebrafish. See table 1 for results of 
NCBI-Blast/blastp with human ADAM17 
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in the family of human ADAM metalloproteases is 
ADAM10 (NP_001101.1), but there is only less than 














































So far no common germinal or somatic mutation 




Various growth factors necessary for tumor progression 
and growth are shed by ADAM17 and increased 
shedding of EGFR ligands was observed in tissues 
developing a malignant phenotype (Katakowski et al., 
2009). ADAM17 is supposed to play a role in different 
malignancies: increased levels of the enzyme were 
detected in gastric carcinoma (Yoshimura et al., 2002), 
primary colon carcinoma (Blanchot-Jossic et al., 2005), 
skin malignancies (Oh et al., 2009) and ovarian cancer 
(Tanaka et al., 2005) but its role is best studied in 
breast cancer (see below). 
Breast cancer 
Disease 
It was shown that overexpression of ADAM17 in breast 
cancer correlated with TGFalpha expression (Borrell-
Pages et al., 2003), metastasis and tumor progression 
(McGowan et al., 2007) and shorter survival of patients 
(McGowan et al., 2008). Recent studies by Kenny and 
Bissell demonstrated that the malignant phenotype of a 
breast cancer cell line was reverted to a normal 




The identification of ADAM17 as TNFalpha 
converting enzyme suggested an important role of this 
metalloprotease in inflammatory diseases with elevated 
levels of soluble TNFalpha, such as rheumatoid 
arthritis and inflammatory bowel disease. Indeed, 
increased enzymatic activity of ADAM17 was shown 
in tissues of patients with osteoarthritis (Amin, 1999) 
and rheumatoid arthritis (Ohta et al., 2001). 
Furthermore ADAM17 was shown to process several 
factors that are involved in leukocyte recruitment to he 
site of inflammation. Moreover ADAM17 regulates 
leukocyte transmigration through the vascular 
endothelium for example by cleaving adhesion 
molecules between endothelial cells. The vascular cell 
adhesion molecule (CC: TXT: V-CAM ID: 42784>) is 
released by ADAM17 and functions as the ligand of the 
leukocyte very late antigen 4 (VLA-4 or alpha4beta1 
integrin), which is implicated in the leukocyte adhesion 
to the vascular endothelium (Garton et al., 2003).  
 
 
L-Selectin cleavage by ADAM17 promotes leukocyte 
migration through the basal membrane after adhering to 
the endothelium (Faveeuw et al., 2001; Peschon et al., 
1998). ADAM17 was also identified as the sheddase of 
the tight junction molecule JAM-1 between endothelial 
cells (Koenen et al., 2009). Cleavage of JAM-1 
contributes to the passage of leukocytes through the 
endothelial cell layer and the processed molecule 
serves as a biomarker of inflammation. 
Disease 
- rheumatoid arthritis (see above),  
- osteoarthritis (see above),  
- inflammatory bowel disease (high levels of ADAM17 
expression were reported in epithelial cells during the 
active phase of Crohn's disease (Cesaro et al., 2009)),  
- psoriasis (ADAM17 expression was upregulated in 
keratinocytes, blood vessels and mast cells from 
patients (Kawaguchi et al., 2005)),  
- pulmonary inflammation (reduced invasion of 
eosinophils in a model of acute allergic lung 
inflammation after treatment with ADAM17/MMP 
inhibitors (Trifilieff et al., 2002)). 
Alzheimer's disease 
Note 
The majority of the amyloid precursor protein (APP) is 
physiologically cleaved by alpha-secretase (ADAM10 
or ADAM17). This cleavage leads to the generation of 
a soluble non-amyloidogenic fragment (sAPPalpha), 
whereas shedding of APP by beta-secretase produces 
the amyloidogenic Abeta peptide (Allinson et al., 
2003). Accordingly, decreased activity of alpha-
secretase results in the formation of amyloid plaques. 
While ADAM10 represents the most important alpha-
secretase, ADAM17 could contribute to APP-
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processing under certain conditions (Buxbaum et al., 
1998; Jorissen et al., 2010). 
Kidney diseases 
Note 
In polycystic kidney disease (PDK) increased 
activation of the EGF receptor leads to cyst formation 
and loss of kidney function. These symptoms could be 
significantly decreased by treatment with ADAM17 
inhibitors (Richards et al., 1998; Dell et al., 2001). 
Which EGFR ligand is responsible in this context 
remains unclear, but TGFalpha knockout mice were 
shown to still develop PDK (Nemo et al., 2005). 
ADAM17 is also involved in chronic kidney disease 
(CDK) and it is suggested that this is due to the 
transactivation of EGFR through the GPCR agonist 
angiotensin-II (Lautrette et al., 2005). In this process 
ADAM17 is activated by the GPCR and releases 
TGFalpha, which in turn activates the EGFR. 
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